Geron surges after blood disorder drug gets FDA advisers' backing

Geron

15/03/2024 10:05

** Shares of drug developer Geron  GERN.O  rise 77.1% to
$3.10 premarket
    ** Stock is the top performer across U.S. exchanges
    ** Late on Thursday, advisers to the U.S. FDA backed
benefits of company's blood disorder drug, imetelstat, saying it
outweighed the risks such as low red blood cell count in
patients treated with it
    ** The panel voted in favor of the drug by a wide 12-to-2
margin 
    ** GERN is seeking approval for imetelstat to treat
transfusion-dependent anemia in patients with a group of blood
cancers called myelodysplastic syndromes (MDS)
    ** The FDA is expected to make a decision on imetelstat by
June 16
    ** Up to last close, stock down 17.1% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com))